Clinical Trial: NCT03793140
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
Official Title
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Conditions
Lymphoma, Leukemia
Intervention / Treatment
- Drug: CPI-613
Other Study ID Numbers
- 18-443
Start Date (Actual)
2018-12-31
Primary Completion Date (Actual)
2026-08-25
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-08-27 |
Study Overview
Brief Summary
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
Official Title
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Conditions
Lymphoma, Leukemia
Intervention / Treatment
- Drug: CPI-613
Other Study ID Numbers
- 18-443
Start Date (Actual)
2018-12-31
Primary Completion Date (Actual)
2026-08-25
Study Completion Date (Actual)
2026-08-25
Enrollment (Actual)
24
Study Type
Interventional
Phase
Phase 2